ALL
2022
2021
2020~2015
July 25, 2022
Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board
Apr 13, 2022
SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)
Jan 06, 2022
SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants
Nov 19, 2021
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing
Jun 23, 2021
SyneuRx Announces Closing of Public Offering
Jun 08, 2021
Taiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial
Jun 03, 2021
SyneuRx Files an IND Application for COVID-19 Clinical Trial in Taiwan SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19
Apr 27, 2021
SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19
Mar 26, 2021
US FDA Approves SyneuRx’s IND Application for a Phase II Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms
Mar 08, 2021
TFDA Approves SyneuRx's Schizophrenia Trials in Taiwan as part of its Global Schizophrenia Trials
Feb 26, 2021
Ω-NaBen, the Ultimate and Supreme Sodium Benzoate
Feb 04, 2021
US FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19
Sep 10, 2018
SyneuRx’s SNS Patent Applications Have Been Granted in Taiwan and in the US.
May 22, 2017
First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia
May 11, 2017
FDA Approves SyneuRx’ IND Application for Late Phase Clinical DeveloFirst Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trialpment of a Mild Dementia Treatment SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults
Apr 04, 2016
FDA Approves SyneuRx’ IND Application for Late Phase Clinical Development of a Mild Dementia Treatment SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults
Dec 19, 2015
SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults
Cart
